ENHANCED p53-DEPENDENT GROWTH INHIBITION OF HUMAN GLIOBLASTOMA CELLS BY COMBINATORIAL TREATMENT OF TEMOZOLOMIDE AND NOVEL PURIFIED NATURAL CARBOHYDRATE OF PLEUROTUS FLORIDA
DOI:
https://doi.org/10.22159/ijpps.2017v9i6.18002Keywords:
Glioblastoma, Combinatorial treatment, Edible mushroom, Cell cycle, Carbohydrate, p53Abstract
Objective: This study was designed to analyze the combinatorial chemotherapeutic effect of temozolomide (TMZ), the most common drug in glioblastoma treatment and a purified carbohydrate (Fr-II) from the edible mushroom Pleurotus florida, on human glioblastoma cell lines.
Methods: Fr-II was purified by size-exclusion chromatography and characterised by different mass spectroscopy analysis. Human glioblastoma cells were treated with TMZ, Fr-II, and combination of TMZ and Fr-II. Cell cytotoxicity was measured by MTT assay, cell cycle phase distribution was determined by cell cycle analysis and followed by the relative p53 protein expression was analyzed by western blot analysis.
Results: Chemical analysis of Fr-II confirmed the glycosidically linked two units of glucose with terminally attached mannitol with mass of 506 Da. Fr-II treatment exhibited cytotoxicity in both the cell lines in a dose-dependent manner with most effective dose at 200µg/ml. When Fr-II (200µg/ml) was combined with a dose range of TMZ it showed a more cellular cytotoxicity compared to the cytotoxicity of TMZ alone with most oppressive combinatorial dose at 400µM (TMZ)+200µg/ml (Fr-II). In compliance, with the above results, both cell lines showed a 10% increase in no. of cells (p<0.05) in G2/M phase indicating an arrest of cell cycle and increased p53 protein expression (p<0.05) at the combinatorial dose than TMZ alone at 400µM, but Fr-II alone didn't show any cell cycle arrest nor did it show increased p53 expression.
Conclusion: Therefore it confirms that Fr-II synergizes with TMZ to significantly intensify its anti-proliferative properties, thereby emerging as an effective element for combinatorial treatment of glioblastoma.
Downloads
References
Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001;12:259-66.
Zhang J, Stevens MF, Bradshaw TD. Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol 2012;5:102-14.
Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 2010;10:319-31.
Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L. Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 2007;56:275-87.
Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000;5:144-51.
Yin LT, Fu YJ, Xu QL, Yang J, Liu ZL, Liang AH, et al. Potential biochemical therapy of glioma cancer. Biochem Biophys Res Commun 2007;362:225-9.
Katayama M, Kawaguchi T, Berger MS, Pieper RO. DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 2007;14:548-58.
Kim JT, Kim JS, Ko KW, Kong DS, Kang CM, Kim MH, et al. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep 2006;16:33-9.
Hickman MJ, Samson LD. Apoptotic signalling in response to a single type of DNA lesion, O6-methylguanine. Mol Cell 2004;14:105-16.
Hirose Y, Berger MS, Pieper RO. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 2001;61:1957-63.
Mhaidat NM, Zhang XD, Allen J, Avery-Kiejda KA, Scott RJ, Hersey P. Temozolomide induces senescence but not apoptosis in human melanoma cells. Br J Cancer 2007;97:1225-33.
Uzzaman M, Keller G, Germano IM. Enhanced proapoptotic effects of tumor necrosis factor–related apoptosis-inducing ligand on temozolomide-resistant glioma cells. J Neurosurg 2007;106:646-51.
Meer L, Janzer RC, Kleihues P, Kolar GF. In vivo metabolism and reaction with DNA of the cytostatic agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC). Biochem Pharmacol 1986;35:3243-7.
Mrugala M. Advances and challenges in the treatment of glioblastoma: a clinician’s perspective. Discovery Med 2013;15:221-30.
Davis BG, Robinson MA. Drug delivery systems based on sugar-macromolecule conjugates. Curr Opin Drug Discovery Dev 2002;5:279-88.
Cheung PCK. Mini-review on edible mushrooms as a source of dietary fiber: Preparation and health benefits. Food Sci Human Wellness 2013;2:162-6.
Valverde ME, Hernández-Pérez T, Paredes-López O. Edible mushrooms: improving human health and promoting quality life. Int J Microbiol 2015;376-8. Doi:10.1155/2015/376387.
Moradali MF, Mostafavi H, Ghods S, Hedjaroude GA. Immunomodulating and anticancer agents in the realm of micromycetes fungi (macrofungi). Int J Immunopharmacol 2007;7:701-24.
Chen Y, Xie MY, Nie SP, Li C, Wang YX. Purification, composition analysis and antioxidant activity of a polysaccharide from the fruiting bodies of Ganoderma atrum. Food Chem 2008;107:231-41.
Kishida E, Sone Y, Misaki A. Effects of branch distribution and chemical modifications of antitumor (1 → 3)-β-d-glucans. Carbohydr Polym 1992;17:89-95.
Dey B, Bhunia SK, Maity KK, Patra S, Mandal S, Maiti S, et al. Chemical analysis of an immune-enhancing water-soluble polysaccharide of an edible mushroom, Pleurotus florida blue variant. Carbohydrate Res 2010;345:2736-41.
Rout D, Mondal S, Chakraborty I, Pramanik M, Islam SS. Structural characterisation of an immunomodulating polysaccharide isolated from an aqueous extract of Pleurotus florida fruit-bodies. Med Chem Res 2004;13:509-17.
Ahmed SA, Kadam JA, Mane VP, Patil SS, Baig MMV. Biological efficiency and nutritional contents of Pleurotus florida (Mont.) singer cultivated on different agro-wastes. Nat Sci 2009;7:44-8.
Jose N, Janardhanan KK. Antioxidant and antitumor activity of Pleurotus florida. Curr Sci 2000;79:941-3.
DuBois M, Gilles KA, Hamilton JK, Rebers PA, Smith F. Colorimetric method for determination of sugars and related substances. Anal Chem 1956;28:350-6.
Khatua B, Vleet JV, Choudhury BP, Chaudhry R, Mandal C. Sialylation of outer membrane porin protein D: a mechanistic basis of antibiotic uptake in Pseudomonas aeruginosa. Mol Cell Proteomics 2014;13:1412-28.
Ogata S, Shimizu C, Franco A, Touma R, Kanegaye JT, Choudhury BP, et al. Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G. PLoS One 2013;8:e81448.
Kumar S, Acharya R, Chatterji U, De P. Controlled synthesis of β-sheet polymers based on side-chain amyloidogenic short peptide segments via RAFT polymerization. Polymer Chem 2014;5:6039-50.
Roy P, Das S, Mondal A, Chatterji U, Mukherjee A. Nanoparticle engineering enhances anticancer efficacy of andrographolide in MCF-7 cells and mice bearing EAC. Curr Pharma Biotech 2012;13:2669-81.
Chatterjee A, Chatterji U. Arsenic abrogates the estrogen-signaling pathway in the rat uterus. Reprod Biol Endocrin 2010;8:80.
Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
Saka S, Singh An, Sharma N. Potential anti-cancer superfoods: a minireview. Int J Curr Pharm Res 2016;8:19-21.
Hafeez Aa, Rakha Om. Paederus Alfieri extract induces apoptosis in human myeloid leukemia K562 cells. Asian J Pharm Clin Res 2017;10:72-5.
Published
How to Cite
Issue
Section
